Last updated: 2026-09-08 13:12:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Enovis Corporation (ENOV) operates in the ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES sector and is listed on NYSE. The stock is currently priced at $19,16, with a market capitalization of $1,07B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $18,52 to $34,28. This page covers its latest market performance, valuation, price trends and company information.
$1,07B | |
$18,55 | |
$72,13 | |
$18,52 | |
$18,56 | |
25,82K | |
1,23M | |
-- | |
$34,28 | |
$18,52 | |
-- | |
-- |
Enovis Corporation (ENOV) is trading at $19,16 in pre-market trading as of 2026-09-08 13:08:00, up 3,23% ($0,60) from the previous close of $18,56
Pre-market trading shows how investors are pricing ENOV before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Enovis Corporation (ENOV) moved from $24,83 to $19,16, representing a decline of 22,84% ($5,67).
The stock traded between $18,52 and $25,40 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,79 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 4,1%
ENOV is currently trading at $19,16, placing it 4,1% of the way from its 52-week low of $18,52 to its 52-week high of $34,28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
| Industry | ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES |
| Employees | 7802 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Enovis Corporation (ENOV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.